Cardiac Amyloid Deposits and Heart Dysfunction in Alzheimer's Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Essen
About this trial
This study seeks to explore the possible common pathogenesis of both cardiac amyloidosis and Alzheimer's disease, which can both be associated with amyloid deposits. Using Positron Emission Tomography (PET) scans with amyloid tracers - a conventional tool for non-invasively imaging amyloid deposits in Alzheimer's disease - the research will extend this imaging methodology to the heart.
The study will conduct additional PET/MRI scans of the heart in patients undergoing amyloid tracer PET scans for Alzheimer's evaluations. Each participant will also undergo an echocardiogram and a clinical examination of dementia.
This could potentially enhance diagnostic practices in both cardiac amyloidosis and Alzheimer's disease.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients undergoing cerebral amyloid PET examination for clinical indication to clarify Alzheimer's disease
No contraindications to undergo an MRI examination
No contraindications to undergo an Amyloid PET scan
Disqualifiers
Patients with vascular dementia and confirmed other causes of dementia (e.g. stroke, vitamin deficiency, thyroid insufficiency, toxic causes such as alcohol)
Patients with pronounced cardiac preconditions
Pregnant and breastfeeding women
Trial population
The study population consists of patients who have been clinically referred for a cerebral amyloid PET examination to clarify a diagnosis of Alzheimer's disease. The study aims to recruit a diverse group of patients, aged 50-90 years, with a minimum of 7 years of education and good knowledge of the German language. Patients will be accompanied by a companion during the study. Excluded from the study will be patients with vascular dementia or other confirmed causes of dementia, such as stroke, vitamin deficiency, thyroid insufficiency, or toxic causes like alcohol. Additionally, patients with pronounced cardiac preconditions, pregnant women, and breastfeeding women will be excluded. The study population will be recruited from a clinical setting, where patients are undergoing routine diagnostic tests for Alzheimer's disease.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
15 Participants
are grouped into 1 trial groupGroup A: Patients referred for cerebral amyloid PET to clarify Alzheimer's disease
Trial outcomes
Primary outcomes
1
Frequency of occurrence of cardiac amyloid deposits in patients with a diagnosis of Alzheimer's disease (overall)
Time frame
through study completion, an average of 1 year2
Frequency of occurrence of cardiac amyloid deposits in relation to different disease manifestations (subdivided, for example, by clinical assessment of disease stage)
Time frame
through study completion, an average of 1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov